Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from InMed Pharmaceuticals ( (INM) ) is now available.
On April 21 and April 24, 2026, InMed Pharmaceuticals entered into amending agreements to significantly reduce the exercise prices on existing preferred investment options held by Sabby Volatility Warrant Master Fund and three affiliates of H.C. Wainwright & Co. The Sabby options for up to 2,151,478 common shares had their exercise price cut from $2.436 to $0.80, while the Wainwright options for up to 153,236 common shares saw exercise prices as high as $82.50 similarly reset to $0.80 per share.
Announced via press release on April 27, 2026, the repricing aims to make the privately placed options more economically attractive to holders, potentially facilitating future exercises and providing InMed with an avenue for additional equity financing. The move may enhance the likelihood of near- to medium-term capital inflows without issuing new option grants, though there is no assurance that any of the preferred investment options will ultimately be exercised, leaving the timing and scale of any dilution or funding benefits uncertain for existing shareholders.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is weighed down primarily by weak financial fundamentals (large ongoing losses and cash burn despite improving revenue) and bearish technicals (below all key moving averages with negative MACD). Corporate events are mixed but include meaningful listing and business-transition risk, while valuation inputs are not meaningful/supportive based on the provided P/E and missing dividend yield.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a Nasdaq-listed pharmaceutical company developing a pipeline of proprietary small molecule drug candidates targeting the CB1 and CB2 receptors for diseases with high unmet medical needs. Through its subsidiary BayMedica, it is also a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary small molecule analogs, with programs in Alzheimer’s, ocular and dermatological indications.
Average Trading Volume: 106,394
Technical Sentiment Signal: Sell
Current Market Cap: $2.56M
For a thorough assessment of INM stock, go to TipRanks’ Stock Analysis page.